JP Morgan Rates QuidelOrtho (QDEL) sell, $12 Price Target

JP Morgan maintains its sell rating on QuidelOrtho, setting a $12 price target, a 31.51% downside from the current price.

By EarningsIQ Research Desk · Published Jul 1, 2026, 11:01 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

JP Morgan rated QuidelOrtho Corporation ($QDEL) "sell" with a $12 price target on July 1, 2026.

Since the rating, $QDEL is down 5.1% after 1 week, down 7.8% after 1 month and down 29.0% to date (from the $18.18 close on Jul 1, 2026).

QDEL QuidelOrtho Corporation

$12.91 -55.14% year to date

Daily close · Oct 16, 2026

Key Points

JP Morgan reiterated its sell rating on QuidelOrtho Corporation (QDEL) with a $12 price target on July 1, 2026.
JP Morgan's $12 price target implies 31.51% downside from QuidelOrtho Corporation's ($QDEL) current $17.52 share price.
Shares of QDEL traded at $17.52 on Wednesday, with the company having a market cap of about $1.19 billion.
Analysts from JP Morgan, Jefferies, Citigroup, and UBS have various ratings, with JP Morgan's being the most bearish.

Get $QDEL trade alerts by text

We text you when insiders, Congress or big funds trade $QDEL. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated QuidelOrtho Corporation alert may contain errors. Disclosures

JP Morgan has reiterated its sell rating on QuidelOrtho Corporation (NasdaqGS: QDEL), setting a price target of $12. This decision was announced on July 1, 2026, by analyst Casey Woodring. The stock traded at $17.52 on Wednesday.

Analyst rating track record

JP Morgan vs. the S&P 500

YTD return -2.44% hypothetical

All-time return +35.01% S&P 500 +38.77%

vs. S&P 500 -3.76% behind the index

Hypothetical returns from JP Morgan's disclosed trades, not real profit or advice. How we model this.

QuidelOrtho Corporation Stock Up 65.0%

Shares of QuidelOrtho traded near $17.52 on Wednesday. The company has a market cap of about $1.19 billion and a forward P/E ratio of 7.18. Its beta is 0.759, indicating lower volatility compared to the market. The stock has seen a 52-week low of $9.92 and a high of $35.58, with a 50-day moving average of $12.60 and a 200-day moving average of $22.17. The company's debt-to-equity ratio is quite high at 155.27.

12-month forecast

$QDEL price target

QuidelOrtho Corporation daily closes and this analyst's $12 target. Not advice.

Recent Earnings

QuidelOrtho reported revenue of approximately $2.66 billion, although it experienced a revenue decline of 10.5%. The company is not currently profitable, with a net margin of -45.57% and a return on equity of -49.95%. The next earnings report is scheduled for July 29, 2026.

Insider Buying and Selling at QuidelOrtho Corporation

Several insiders made recent purchases on June 25, 2026. John Chiminski acquired 1,109 shares, while Edward Michael bought 1,053 shares. Mary Lake Ph Polan purchased 15,532 shares, and Kenneth Widder acquired a total of 17,529 shares across two transactions. Kenneth Buechler also bought 3,661 shares. These transactions were not part of any pre-planned trading program.

Analysts Set New Price Targets

On July 1, 2026, JP Morgan maintained its sell rating on QuidelOrtho with a $12 price target. Previously, on May 7, 2026, Jefferies downgraded the stock to a hold rating with a $12.50 target. Citigroup and UBS have maintained hold ratings with targets of $13 and $17, respectively. The consensus among analysts is a hold rating, with an average price target of $18.63 based on four analyst opinions.

About QuidelOrtho Corporation

QuidelOrtho Corporation, headquartered in San Diego, CA, provides diagnostic testing solutions. Operating in the healthcare sector, the company focuses on medical devices. It has four main business units: Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics. QuidelOrtho's products are used globally across various healthcare settings. The company was founded in 1979 and employs about 6,500 people.

Bottom Line

JP Morgan's reiterated sell rating on QuidelOrtho with a $12 target reflects a bearish outlook. Investors often watch these ratings closely, though it's important to remember that analyst opinions are just one piece of the puzzle. QuidelOrtho's financials reveal challenges with profitability, and upcoming earnings will be critical to watch. As always, 13F filings and analyst reports are backward-looking, providing a snapshot of past activities and opinions.